• O.O. Sherstyuk Poltava state medical university
  • Y.V. Sarychev Poltava state medical university
  • S.M. Suprunenko Poltava state medical university
  • S.A. Sukhomlin Poltava state medical university
  • G.L. Pustovoit Poltava state medical university
Keywords: benign prostatic hyperplasia, urinary bladder, morphology


We conducted an analytical review of the literature on the problem of bladder decompensation in patients with benign prostatic hyperplasia. Benign prostatic hyperplasia is one of the most common diseases in aging men. As is known, with the development of benign prostatic hyperplasia due to infravesicular obstruction, the resistance to urine flow increases. As a result of a prolonged overload, the bladder is restructured, and it goes through three successive stages: compensation, subcompensation, and decompensation. Irreversible changes develop in the epithelial, muscular, and nerve tissues of the bladder. With benign prostatic hyperplasia due to intravesical hypertension, persistent microcirculation disorders occur in the walls of the bladder, which leads to the appearance of chronic detrusor ischemia, and can be a predictor of its fibrotic changes and decompensation. There is a correlation between the pathology of the vascular system and the development of symptoms of the lower urinary tract against the background of benign prostatic hyperplasia. Improvement of lower urinary tract perfusion can be considered a therapeutic strategy for the treatment of bladder dysfunction.


Download data is not yet available.


Fusco F, Creta M, Imperatore V, Longo N, Imbimbo C, Lepor H, et al. Benign prostatic obstruction relief in patients with lower urinary tract symptoms suggestive of benign prostatic enlargement undergoing endoscopic surgical procedures or therapy with alpha-blockers: a review of urodynamic studies. Adv Ther. 2017;34(4):773-83. doi: 10.1007/s12325-017-0504-0.

Sarychev L, Savchenko R, Sarychev Y, Sukhomlyn S, Pustovoyt H. Rehabilitation of Patients with Benign Prostate Hyperplasia with Urinary Bladder Decompensation. Health of Man. 2021;76(1):53–7. doi: 10.30841/2307-5090.1.2021.232489.

Sоnksen J, Barber NJ, Speakman MJ, Berges R, Wetterauer U, Greene D, Sievert

KD, Chapple CR, Montorsi F, Patterson JM, Fahrenkrug L, Schoenthaler M, Gratzke C. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. Eur Urol. 2015;68(4):643-52.

Wang X, Su Y, Yang C, Hu Y, Dong JY. Benign prostatic hyperplasia and cardiovascular risk: a prospective study among Chinese men. World Journal of Urology. 2022;40(1):177-83.

Fusco F, Creta M, Imperatore V, Longo N, Imbimbo C, Lepor H, Mirone V. Benign Prostatic Obstruction Relief in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Enlargement Undergoing Endoscopic Surgical Procedures or Therapy with Alpha-Blockers: A Review of Urodynamic Studies. Adv Ther. 2017;34(4):773-783.

Kim M, Jeong CW, Oh SJ. Effect of preoperative urodynamic detrusor underactivity on transurethral surgery for benign prostatic hyperplasia: a systematic review and meta-analysis. J Urol. 2018;199(1):237-44. doi: 10.1016/j.uro.2017.07.079.

Pasiechnikov SP, Vozianov SA, Lisovyi VM. Urology. Vinnytsia: Nova Knyha 2019; p. 274-89. [in Ukrainian]

Gravas S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C, et. al. EAU Guidelines on Non-Neurogenic Male LUTS Including Benign Prostatic Obstruction. EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam Arnhem [Internet]. Netherlands: EAU Guidelines Office 2020; Available from:

Langan RC. Benign prostatic hyperplasia. Prim Care. 2019;46(2):223-32. doi: 10.1016/j.pop.2019.02.003

Agarwal V, Yadav SS, Kumar S, Mehta N, Talwar G, Qadri J, Sarwar S. Evaluating the role of extracellular vesicles as a biomarker under transmission electron microscope in prostate cancer and benign prostate hyperplasia patients. Urologia Journal. 2022;89(2):210-215. doi:10.1177/03915603211018677

Jiang YH, Lee CL, Kuo HC. Urothelial dysfunction, suburothelial inflammation and altered sensory protein expression in men with bladder outlet obstruction and various bladder dysfunctions: correlation with Urodynamics. J Urol.2016;196(3):831-7. doi: 10.1016/j.juro.2016.02.2958.

Goi Y, Tomiyama Y, Nomiya M, Sagawa K, Aikawa K, Yamaguchi O. Effects of Silodosin, a Selective alpha1A-Adrenoceptor Antagonist, on Bladder Blood Flow and Bladder Function in a Rat Model of Atherosclerosis Induced Chronic Bladder Ischemia without Bladder Outlet Obstruction. J. Urol. 2013; 190: 1116–22.

Abrams P, Cardozo E, Fail Mf, Griffiths D, Rosier P, UlmstenU, et al.. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167.

Loloi J, Clearwater W, Schulz A, Suadicani SO. Abraham N. Medical Treatment of Overactive Bladder. Urologic Clinics. 2022;49(2):249-261. doi:10.1016/j.ucl.2021.12.005.

Sarychev LP, Starchenko II, Savchenko RB, Sarychev YV, Pustovoit HL. Kliniko-morfolohichne obhruntuvannia likuvalnoi taktyky u khvorykh na dobroiakisnu hiperplaziiu peredmikhurovoi zalozy [Clinical and morphological justification of treatment tactics in patients with benign prostatic hyperplasia]. Urolohyia. 2020; 94(3): 237-8. [In Ukrainian]

Chappie C.R., Roehrborn C.G. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tracy symptoms in men: focus on the bladder // Eur Urol, 2006,49:651-659.

Koritsiadis G, Stravodimos K, Koutalellis G et al. Immunohistochemical estimation of hypoxia in human obstructed bladder and correlation with clinical variables. BJU Int. 2008; 102: 328–32.

Speich JE, Tarcan T, Hashitani H, Vahabi B, McCloskey KD Anderson KE et al. Are oxidative stress and ischemia significant causes of bladder damage leading to lower urinary tract dysfunction? Report from the ICI RS 2019. Neurourol Urodyn. 2020;39:16-22. doi: 10.1002/nau.24313.

Takahashi S, Kato D, Tabuchi H, Uno S. Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post‐marketing study. LUTS: Lower Urinary Tract Symptoms. 2021;13(1):79-87.

De Nunzio C, Brucker B, Bschleipfer T, Cornu JN, Drake MJ, Fusco F, Madersbacher S. Beyond antimuscarinics: a review of pharmacological and interventional options for overactive bladder management in men. European urology. 2021;79(4):492-504.

Kasman A, Stave C, Elliott CS. Combination therapy in overactive bladder‐untapped research opportunities: a systematic review of the literature. Neurourology and Urodynamics. 2019;38(8):2083-92.

Fırat E, Aybek Z, Akgün Ş, Küçüker K, Akça H, Aybek H. Exploring biomarkers in the overactive bladder: Alterations in miRNA levels of a panel of genes in patients with OAB. Neurourology and Urodynamics. 2019;38(6):1571-1578.

Montalbetti N, Rooney JG, Rued AC, Carattino MD. Molecular determinants of afferent sensitization in a rat model of cystitis with urothelial barrier dysfunction. Journal of Neurophysiology. 2019;122(3):1136-46.

Jhang JF, Lin TY, Ho HC, Jiang YH, Hsu YH, Birder LA, Kuo HC. Deficits of urothelial cell proliferation, cytoskeleton, and barrier function protein expressions in patients with recurrent and persistent urinary tract infections. LUTS: Lower Urinary Tract Symptoms. 2021;13(2):203-9.

Chen MW, Buttyan R, Levin RM. Genetic and cellular response to unilateral ischemia of the rabbit urinary bladder. J. Urol. 1996;155(2):732-7.

Hockey JS, Fry CH,. Wu C, Osborn JX. Hypoxia and pathophysiology of idiopathic detrusor instability. Neurourol Urodyn. 1996;15(4):420-1.

Wiafe B, Adesida A, Churchill T, Adewuyi EE, Li Z, Metcalfe, P. Hypoxiaincreased expression of genes involved in inflammation, dedifferentiation, pro-fibrosis, and extracellular matrix remodeling of human bladder smooth muscle cells. In Vitro Cell Dev Biol Anim. 2017;53(1):58-66. doi: 10.1007/s11626-016-0085-2.

Scheepe JR, Amelink A, Wolffenbuttel KP, De Jong BWD, Kok DJ. Changes in bladder wall perfusion in the overactive obstructed bladder. Eur Urol Suppl. 2010;9(2):114.

Pinggera GM, Mitterberger M, Steiner E, Pallwein L, Frauscher F, Aigner F, Strasser H. Association of lower urinary tract symptoms and chronic ischaemia of the lower urinary tract in elderly women and men: assessment using colour Doppler ultrasonography. BJU Int. 2008; 102: 470–4.

Nomiya M, Burmeister DM, Sawada N et al. Effect of melatonin on chronic bladder-ischaemia-associated changes in rat bladder function. BJU Int. 2013; 112:


Ponholzer A, Temml C, Wehrberger C, Marszalek M, Madersbacher S. The association between vascular risk factors and lower urinary tract symptoms in both sexes. Eur. Urol. 2006; 50: 581–6.

Chen LC, Kuo HC. Pathophysiology of refractory overactive bladder. LUTS: Lower Urinary Tract Symptoms. 2019;11(4):177-181.

Berger AP, Horninger W, Bektic J et al. Vascular resistance in the prostate evaluated by colour Doppler ultrasonography: is benign prostatic hyperplasia a vascular disease? BJU Int. 2006; 98: 587–90.

Calogero AE, Burgio G, Condorelli RA, Cannarella R, La Vignera S. Epidemiology and risk factors of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction. The Aging Male. 2019;22(1):12-19.

Matsui S, Kajikawa M, Maruhashi T, Iwamoto Y, Oda N, Kishimoto S, Higashi Y. Endothelial dysfunction, abnormal vascular structure and lower urinary tract symptoms in men and women. International Journal of Cardiology. 2018;261:196-203.

Andersson KE, Nomiya M, Sawada N, Yamaguchi O. Pharmacological treatment of chronic pelvic ischemia. Ther. Adv. Urol. 2014;6:105–14.

How to Cite
Sherstyuk, O., Sarychev, Y., Suprunenko, S., Sukhomlin, S., & Pustovoit, G. (2022). DECOMPENSATED URINARY BLADDER DUE TO BENIGN PROSTATIC HYPERPLASIA (LITERATURE REVIEW). The Medical and Ecological Problems, 26(3-4), 57-62.